Clinical trial Recruiting at 1 site Interventional Ages 65 to 100

Improving dementia treatment assessment methods

Official title: Novel Methods for Clinical Trials in Dementia and Cognitive Decline

Run by The University of Texas Health Science Center at San Antonio · NCT05592678 · Data updated 2026-11-12

This study is testing a new way to see if donepezil can help people with dementia feel better by looking at their thinking skills and daily activities, while also checking if certain markers in the body play a role in how well the treatment works.

Quick facts

Study typeInterventional
Ages65 Years to 100 Years
SexAll
Enrollment200 (estimated)
SponsorThe University of Texas Health Science Center at San Antonio
Academic / other
Locations1 site (San Antonio, Texas)
StatusRecruiting
StartedAugust 5, 2024
Main results expectedNovember 30, 2028
Study endsNovember 30, 2028
Registry record updatedMay 5, 2026
Trial IDNCT05592678 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include ambulatory individuals aged 65-100 with a clinical diagnosis of Alzheimer's Disease or Mild Cognitive Impairment who have competent informants.

Probably not a fit

Patients with significant visual or hearing impairments or those who do not meet the cognitive assessment criteria may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to enhance the evaluation of interventions for dementia and cognitive decline by utilizing a latent variable, referred to as 'δ', which integrates cognitive performance with functional status. The study will involve pre-selecting participants based on their likelihood to benefit from the medication donepezil, which is approved for Alzheimer's Disease, and assessing its effects on dementia severity. Additionally, the trial will explore the role of adipokines as potential biomarkers that could mediate the treatment's effectiveness. Participants will be monitored through remote assessments conducted by caregivers to identify those most likely to respond to the intervention.

Why it matters

Potential benefit: If successful, this study could lead to more effective and personalized treatment strategies for patients with dementia.

How similar studies have gone: Other studies have shown promise in using biomarkers and latent variables to improve treatment outcomes in dementia, suggesting this approach may be viable.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Ambulatory outpatient volunteers with co-informants.
2. Aged 65-100 years
3. Clinical diagnosis of AD, or MCI.
4. Capacity to give informed consent.
5. GDS score (15 item) ≤ 8.
6. No significant visual or hearing impairments
7. Standardized dECog score between 1.0 and 5.0 relative to ADNI's cohort.

Exclusion Criteria:

1. A history of psychosis, including visual hallucinations;
2. History or treatment for Parkinson's, or tremor, or Rapid Eye Movement (REM) behavior disorder;
3. History of bradycardia or syncopal events;
4. Treatment for cancer in the last 5 years (excluding skin cancers);
5. Major surgery in the last year;
6. Treatment for a seizure disorder with anticonvulsants;
7. Treatment for agitation or psychosis with neuroleptics (treatment of anxiety or insomnia allowed);
8. Current treatment with donepezil or any other AChEI or exposure within the last six months
9. With a recently started Donepezil Rx (\< 2 weeks), inability to stop Donepezil treatment for 14 days prior to study enrollment.
10. AChEI treatment not appropriate due to negative risk/benefit ratio based on medical Hx and symptoms during screening. Evaluated by PI and referring clinician.
11. Co-participation in another study that the PI feels would pose a safety risk or adversely affect data integrity of this study.

Where it's running

  • Univeristy of Texas Health Science Center at San Antonio (UTHSCSA)
    San Antonio, Texas, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.